[go: up one dir, main page]

NI200700320A - Inhibidores de la actividad akt - Google Patents

Inhibidores de la actividad akt

Info

Publication number
NI200700320A
NI200700320A NI200700320A NI200700320A NI200700320A NI 200700320 A NI200700320 A NI 200700320A NI 200700320 A NI200700320 A NI 200700320A NI 200700320 A NI200700320 A NI 200700320A NI 200700320 A NI200700320 A NI 200700320A
Authority
NI
Nicaragua
Prior art keywords
akt activity
activity inhibitors
akt
stipulates
compounds
Prior art date
Application number
NI200700320A
Other languages
English (en)
Inventor
Mdonna J Armstrong
Essa H Hu
Iii Michael J Kelly
Yiwei Li
Jun Liang
Kevin John Krodzinak
Michael A Rossi
Philip E Sanderson
Jiabing Wang
Mark E Layton
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NI200700320A publication Critical patent/NI200700320A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención actual estipula compuestos de naftiridina sustituidos que inhiben actividad Akt. En particular, los compuestos descritos inhiben selectivamente una o dos de las isoformas de Akt. La invención también estipula composiciones que comprenden tales compuestos inhibidores y procedimientos para inhibir actividad Akt administrando el compuesto a un paciente en necesidad de tratamiento de cáncer.
NI200700320A 2005-06-10 2007-12-06 Inhibidores de la actividad akt NI200700320A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07

Publications (1)

Publication Number Publication Date
NI200700320A true NI200700320A (es) 2008-06-17

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700320A NI200700320A (es) 2005-06-10 2007-12-06 Inhibidores de la actividad akt

Country Status (22)

Country Link
US (1) US8008317B2 (es)
EP (1) EP1898903B8 (es)
JP (1) JP5055494B2 (es)
KR (1) KR100959771B1 (es)
AU (1) AU2006258124B8 (es)
BR (1) BRPI0611717A2 (es)
CA (1) CA2610888C (es)
CR (1) CR9580A (es)
DK (1) DK1898903T3 (es)
EC (1) ECSP077980A (es)
ES (1) ES2409168T3 (es)
HR (1) HRP20130429T1 (es)
IL (1) IL187690A (es)
MX (1) MX2007015578A (es)
NI (1) NI200700320A (es)
NO (1) NO20080150L (es)
NZ (1) NZ563423A (es)
PL (1) PL1898903T3 (es)
PT (1) PT1898903E (es)
RU (1) RU2421454C2 (es)
TW (1) TW200800166A (es)
WO (1) WO2006135627A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
PL1898903T3 (pl) 2005-06-10 2013-08-30 Merck Sharp & Dohme Inhibitory aktywności Akt
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
US20100022573A1 (en) * 2006-12-06 2010-01-28 Layton Mark E Inhibitors of akt activity
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
BRPI0813999A2 (pt) 2007-07-05 2019-10-01 Array Biopharma Inc ciclopentanos de pirimidil como inibidores de akt proteína cinase
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
MY169738A (en) 2007-08-14 2019-05-14 Bayer Ip Gmbh Fused bicyclic pyrimidines
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8207169B2 (en) * 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
AU2009255329A1 (en) * 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
EP2591674B1 (de) 2008-07-17 2016-01-13 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
WO2010088177A1 (en) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010091808A1 (en) 2009-02-13 2010-08-19 Bayer Schering Pharma Aktiengesellschaft Fused pyrimidines
ES2435804T3 (es) 2009-02-13 2013-12-23 Bayer Intellectual Property Gmbh Pirimidinas condensadas como inhibidores de Akt
US8481503B2 (en) * 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
EP2406250B1 (en) * 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
WO2011075383A1 (en) * 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
EP2593451B1 (en) * 2010-07-12 2015-08-19 Bayer Intellectual Property GmbH Substituted imidazo[1,2-a]pyrimidines and -pyridines
ES2603032T3 (es) * 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
PT2694510E (pt) 2011-04-07 2016-02-08 Bayer Pharma AG Imidazopiridazinas como inibidores da akt quinase
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
KR102123131B1 (ko) * 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
PE20151979A1 (es) 2013-01-23 2016-01-15 Astrazeneca Ab Compuestos quimicos
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3091016A1 (en) * 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
WO2017097216A1 (zh) * 2015-12-07 2017-06-15 杭州雷索药业有限公司 五元杂环酰胺类wnt通路抑制剂
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CA3074641A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
EP4426706A4 (en) * 2021-11-05 2025-10-15 Georgiamune Inc AKT3 MODULATORS
WO2025196161A2 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2025196160A1 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
SK282167B6 (sk) * 1995-06-06 2001-11-06 Pfizer Inc. Tricyklické 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a] pyridíny a farmaceutický prostriedok na ich báze
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
ATE400274T1 (de) 2001-04-10 2008-07-15 Merck & Co Inc Hemmstoffe der akt aktivität
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086394A1 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
BR0313743A (pt) * 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
CN100422158C (zh) 2003-04-24 2008-10-01 麦克公司 Akt活性抑制剂
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7638530B2 (en) * 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
EP1631548B1 (en) * 2003-04-24 2009-10-28 Merck & Co., Inc. Inhibitors of akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
WO2005035506A1 (ja) 2003-10-15 2005-04-21 Ube Industries, Ltd. 新規インダゾール誘導体
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006068796A2 (en) 2004-12-02 2006-06-29 Merck & Co., Inc. Inhibitors of akt activity
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006091395A2 (en) * 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
EP1871376A4 (en) 2005-04-12 2010-04-28 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
PL1898903T3 (pl) 2005-06-10 2013-08-30 Merck Sharp & Dohme Inhibitory aktywności Akt
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
EP1898903A2 (en) 2008-03-19
KR20080016627A (ko) 2008-02-21
JP2009501698A (ja) 2009-01-22
DK1898903T3 (da) 2013-07-01
AU2006258124B2 (en) 2009-09-03
AU2006258124B8 (en) 2010-01-07
NO20080150L (no) 2008-03-10
MX2007015578A (es) 2008-03-06
CR9580A (es) 2008-09-23
JP5055494B2 (ja) 2012-10-24
WO2006135627A3 (en) 2008-07-31
US8008317B2 (en) 2011-08-30
ES2409168T3 (es) 2013-06-25
IL187690A0 (en) 2008-11-03
RU2421454C2 (ru) 2011-06-20
PL1898903T3 (pl) 2013-08-30
CA2610888C (en) 2011-02-08
RU2008100045A (ru) 2009-07-20
ECSP077980A (es) 2008-01-23
HRP20130429T1 (en) 2013-06-30
US20100222321A1 (en) 2010-09-02
KR100959771B1 (ko) 2010-05-28
EP1898903A4 (en) 2010-07-21
EP1898903B1 (en) 2013-03-27
WO2006135627A2 (en) 2006-12-21
EP1898903B8 (en) 2013-05-15
TW200800166A (en) 2008-01-01
CA2610888A1 (en) 2006-12-21
BRPI0611717A2 (pt) 2009-01-13
IL187690A (en) 2012-06-28
AU2006258124A1 (en) 2006-12-21
NZ563423A (en) 2010-05-28
PT1898903E (pt) 2013-06-28

Similar Documents

Publication Publication Date Title
ECSP077980A (es) Inhibidores de la actividad akt
ECSP099376A (es) Inhibidores de la actividad de la akt
WO2006091395A3 (en) Inhibitors of akt activity
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
EA200900227A1 (ru) Пептидомиметики smac, применимые в качестве ингибиторов iap (ингибитор белков апоптоза)
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CR20140544A (es) Compuestos para inhibir la progresión mitotica
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
MX2009003405A (es) Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX379353B (es) Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
WO2006110638A3 (en) Inhibitors of akt activity
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
NI200700323A (es) 4-anilino-3-quinolinocarbonitrilo para el tratamiento de cáncer
WO2007008502A3 (en) Inhibitors of checkpoint kinases
WO2007084135A3 (en) Inhibitors of checkpoint kinases
DOP2009000132A (es) Inhibidores de la actividad de la akt